Team:HKUST-Hong Kong

From 2012.igem.org

(Difference between revisions)
m
Line 456: Line 456:
           <div align="left">
           <div align="left">
               <h1><p align = "center" ><font size=50>B. hercules</font><br>------<i>The Terminator of Colon Cancer</i></p></h1>
               <h1><p align = "center" ><font size=50>B. hercules</font><br>------<i>The Terminator of Colon Cancer</i></p></h1>
-
<p>Millions of cancer patients around the world currently depend on conventional cancer therapies to extend their life. These conventional therapies, composed of surgery, radiotherapy and chemotherapies, have their limitations and shortcomings. Short term and long term side effects include vomiting, hair loss, organ failure or even induction of a second tumor brought about by the spreading toxicity of anti-tumor chemicals in the circulatory system, thus prompting active research into alternative cancer therapies. We, the 2012 HKUST iGEM team, have chosen to focus on colorectal carcinomas, the fourth most common cancer type, as our study object. We aim to use genetically modified <i>Bacillus subtilis</i> to execute targeted drug delivery to cancer cells in the intestinal tract, offering an advantage of minimal harm of the drug to normal colon epithelial cells. <br><br> Our project hopes to modify <i>B. subtilis</i> cells to recognize colon carcinomas. Targeting is to be achieved by expressing a colon tumor specific binding peptide on the cell wall using a cell wall binding system.<br><br> After binding, an anti-tumor chemokine is to be synthesized and secreted out from the bacterial cells with the help of a signaling peptide fused to the protein. To minimize over-production of this tumor suppressor, an inducible production system is introduced. This option of external inducible control will allow us to initiate chemokine release at a time that the effect can be most effective when the killer bacteria are closing in to the colon cancer cells. <br><br> Finally, in consideration of both biosafety issues and the possible harm from an over-dosage of antitumor drug, a toxin-antitoxin system is to be employed in our bacterial vector. We are designing this system to provide a minimum threshold of antitumor drug production and at the same time, minimize the risk from plasmid lateral transfer among gut flora. </p>   
+
<p>Millions of cancer patients around the world currently depend on conventional cancer therapies to extend their life. These conventional therapies, composed of surgery, radiotherapy and chemotherapies, all have their own limitations and shortcomings. Short-term and long-term side effects include vomiting, hair loss, organ failure or even induction of a second tumor brought by the spreading toxicity of anti-tumor chemicals in the circulatory system, thus prompting active research into alternative cancer therapies. We, the 2012 HKUST iGEM team, have chosen to focus on colorectal carcinomas, the fourth most common cancer type around the world, as our study object. We aim to use genetically modified <i>Bacillus subtilis</i> to execute targeted drug delivery to cancer cells in the intestinal tract, offering an advantage of minimal harm of the drug to normal colon epithelial cells. <br><br> Our project hopes to enigneer <i>B. subtilis</i> to make them have the ability to recognize colon carcinomas. This specific targeting is to be achieved by expressing a colon tumor specific binding peptide on the cell wall using a cell wall binding system.<br><br> After binding, an anti-tumor chemokine is to be synthesized and secreted out from the bacterial cells with the help of a signaling peptide fused to the protein. To minimize over-production of this tumor suppressor, an inducible production system is introduced. This option of external inducible control will allow us to initiate chemokine release at a time that the effect can be most effective when the killer bacteria are closing enough to the colon cancer cells. <br><br> Finally, in consideration of both biosafety issues and the possible harm from an over-dosage of antitumor drug, a toxin-antitoxin system is to be employed in our bacterial vector. This system is supposed to provide a minimum threshold of antitumor drug production and at the same time, minimize the risk from plasmid lateral transfer among gut flora. </p>   
           </div>
           </div>
        
        

Revision as of 13:17, 26 September 2012

Team:HKUST-Hong Kong - 2012.igem.org

B. hercules
------The Terminator of Colon Cancer

Millions of cancer patients around the world currently depend on conventional cancer therapies to extend their life. These conventional therapies, composed of surgery, radiotherapy and chemotherapies, all have their own limitations and shortcomings. Short-term and long-term side effects include vomiting, hair loss, organ failure or even induction of a second tumor brought by the spreading toxicity of anti-tumor chemicals in the circulatory system, thus prompting active research into alternative cancer therapies. We, the 2012 HKUST iGEM team, have chosen to focus on colorectal carcinomas, the fourth most common cancer type around the world, as our study object. We aim to use genetically modified Bacillus subtilis to execute targeted drug delivery to cancer cells in the intestinal tract, offering an advantage of minimal harm of the drug to normal colon epithelial cells.

Our project hopes to enigneer B. subtilis to make them have the ability to recognize colon carcinomas. This specific targeting is to be achieved by expressing a colon tumor specific binding peptide on the cell wall using a cell wall binding system.

After binding, an anti-tumor chemokine is to be synthesized and secreted out from the bacterial cells with the help of a signaling peptide fused to the protein. To minimize over-production of this tumor suppressor, an inducible production system is introduced. This option of external inducible control will allow us to initiate chemokine release at a time that the effect can be most effective when the killer bacteria are closing enough to the colon cancer cells.

Finally, in consideration of both biosafety issues and the possible harm from an over-dosage of antitumor drug, a toxin-antitoxin system is to be employed in our bacterial vector. This system is supposed to provide a minimum threshold of antitumor drug production and at the same time, minimize the risk from plasmid lateral transfer among gut flora.

Origin of the name B. hercules

Cancer, as one of the most obstinate diseases, is well-known for its immortal proliferation. Its name is originated from one of the Zodiac ‘Cancer’ which Represents death and reincarnation. Next to Cancer, there is a constellation called Heracles. It is named after the most famous Greek hero Heracles (whose Romans name is Hercules). In Greek myth, Hera sent Karkinos (Cancer or crab in Greek) to distract Heracles in his battle with Hedra, the second labour for Heracles. However, during the battle, Heracles easily smashed the crab’s (Cancer) shell by foot.

B. hercules, our engineered B. subtilis executing anti-tumor function, is named after this hero. We would like to have our hero, B. hercules, combat colon cancer in a breeze and eliminate his enemy, colon cancer, without harming the innocent.

That’s the mission of B. hercules.

Third Paragraph